Hemab Therapeutics (NASDAQ:COAG) Stock Rating Upgraded by Rodman & Renshaw

Hemab Therapeutics (NASDAQ:COAG) was upgraded by analysts at Rodman & Renshaw to a “strong-buy” rating in a report released on Monday, Zacks reports.

COAG has been the topic of several other reports. Weiss Ratings cut Hemab Therapeutics from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday, September 25th. HC Wainwright raised their price objective on Hemab Therapeutics from $52.00 to $60.00 and gave the company a “buy” rating in a research note on Tuesday, August 11th. Jefferies Financial Group lifted their target price on Hemab Therapeutics from $39.00 to $47.00 and gave the stock a “buy” rating in a report on Monday, July 13th. Finally, Wedbush lifted their target price on Hemab Therapeutics from $55.00 to $64.00 and gave the stock an “outperform” rating in a report on Wednesday, August 12th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $52.17.

Hemab Therapeutics Stock Down 1.9%

Shares of NASDAQ:COAG opened at $29.80 on Monday. Hemab Therapeutics has a 52 week low of $23.00 and a 52 week high of $55.42. The stock has a market cap of $1.39 billion and a PE ratio of -1.20. The business has a fifty day simple moving average of $42.06.

Hemab Therapeutics (NASDAQ:COAG) last announced its earnings results on Tuesday, August 11th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by ($0.17). On average, equities research analysts forecast that Hemab Therapeutics will post -3.09 earnings per share for the current year.

Hedge Funds Weigh In On Hemab Therapeutics

Several hedge funds have recently added to or reduced their stakes in COAG. Squarepoint Ops LLC bought a new position in shares of Hemab Therapeutics during the second quarter valued at approximately $230,000. The Manufacturers Life Insurance Company bought a new stake in shares of Hemab Therapeutics during the 2nd quarter worth approximately $688,000. Opaleye Management Inc. bought a new stake in shares of Hemab Therapeutics during the 2nd quarter worth approximately $1,750,000. State Street Corp purchased a new position in Hemab Therapeutics during the 2nd quarter valued at $2,825,000. Finally, Braidwell LP purchased a new position in Hemab Therapeutics during the 2nd quarter valued at $5,877,000.

Hemab Therapeutics Company Profile

Hemab Therapeutics (NASDAQ: COAG) is a clinical-stage biopharmaceutical company developing treatments for serious and potentially life-threatening bleeding disorders. The company focuses on rare conditions for which existing therapies may be limited, inconvenient, or ineffective for some patients.

Hemab’s lead investigational program, HMB-001, is an engineered bispecific antibody designed to improve blood clotting by enhancing thrombin generation through inhibition of tissue factor pathway inhibitor.